Preferred shares, authorized (in shares)

[Table of Contents](#ib0ff9808fe764fdea19589324372f96b_7)Abbott Laboratories and SubsidiariesCondensed Consolidated Balance Sheet(Unaudited)(dollars in millions)

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  |  |  |  |  |  |  |  |  |  |  |  |
|  | September 30,2022 |  | December 31,2021 |
| Assets |  |  |  |
| Current Assets: |  |  |  |
| Cash and cash equivalents | $ | 9,594  |  |  | $ | 9,799  |  |
| Short-term investments | 313  |  |  | 450  |  |
| Trade receivables, less allowances of $520 in 2022 and $519 in 2021 | 6,408  |  |  | 6,487  |  |
| Inventories: |  |  |  |
| Finished products | 3,407  |  |  | 3,081  |  |
| Work in process | 726  |  |  | 694  |  |
| Materials | 1,601  |  |  | 1,382  |  |
| Total inventories | 5,734  |  |  | 5,157  |  |
| Prepaid expenses and other receivables | 2,796  |  |  | 2,346  |  |
| Total Current Assets | 24,845  |  |  | 24,239  |  |
| Investments | 764  |  |  | 816  |  |
| Property and equipment, at cost | 19,306  |  |  | 19,364  |  |
| Less: accumulated depreciation and amortization | 10,617  |  |  | 10,405  |  |
| Net property and equipment | 8,689  |  |  | 8,959  |  |
| Intangible assets, net of amortization | 10,850  |  |  | 12,739  |  |
| Goodwill | 22,284  |  |  | 23,231  |  |
| Deferred income taxes and other assets | 5,369  |  |  | 5,212  |  |
|  | $ | 72,801  |  |  | $ | 75,196  |  |
| Liabilities and Shareholders’ Investment |  |  |  |
| Current Liabilities: |  |  |  |
| Trade accounts payable | $ | 4,133  |  |  | $ | 4,408  |  |
| Salaries, wages and commissions | 1,426  |  |  | 1,625  |  |
| Other accrued liabilities | 5,475  |  |  | 5,181  |  |
| Dividends payable | 820  |  |  | 831  |  |
| Income taxes payable | 394  |  |  | 306  |  |
| Current portion of long-term debt | 1,117  |  |  | 754  |  |
| Total Current Liabilities | 13,365  |  |  | 13,105  |  |
| Long-term debt | 15,297  |  |  | 17,296  |  |
| Post-employment obligations, deferred income taxes and other long-term liabilities | 8,255  |  |  | 8,771  |  |
| Commitments and Contingencies |  |  |  |
| Shareholders’ Investment: |  |  |  |
| Preferred shares, one dollar par value Authorized — 1,000,000 shares, none issued | —  |  |  | —  |  |
| Common shares, without par value Authorized — 2,400,000,000 shares Issued at stated capital amount — Shares: 2022: 1,985,919,440; 2021: 1,985,273,421 | 24,560  |  |  | 24,470  |  |
| Common shares held in treasury, at cost — Shares: 2022: 242,345,663; 2021: 221,191,228 | (14,555) |  |  | (11,822) |  |
| Earnings employed in the business | 35,115  |  |  | 31,528  |  |
| Accumulated other comprehensive income (loss) | (9,445) |  |  | (8,374) |  |
| Total Abbott Shareholders’ Investment | 35,675  |  |  | 35,802  |  |
| Noncontrolling Interests in Subsidiaries | 209  |  |  | 222  |  |
| Total Shareholders’ Investment | 35,884  |  |  | 36,024  |  |
|  | $ | 72,801  |  |  | $ | 75,196  |  |

The accompanying notes to the condensed consolidated financial statements are an integral part of this statement.5
